ARCHIVES

ASCO’s Lichter Says. Dingell, Stupak Urge FDA To “Act With Due Haste To Avoid Endangering Patients” Steered To ESAs.

This article is from The Cancer Letter archive.

Vol. 34 No. 09 | March 7, 2008

Download PDF Visit The Full Archive

Related Articles

Waxman To Introduce Reauthorization Bill Next Month, Intends To Complete Action By Session End

July 22, 1988

FDA Approvals: Cobas HPV Test Approved For Primary Cervical Screening

April 25, 2014

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

December 2, 1983

NCAB Members Skeptical On NCI Reorganization; King Has “Alterative;” Terry T Head Centers

January 27, 1978

Genentech Move Nixes Hospital Discounts: Avastin, Herceptin, Rituxan Now Sold Under Tighter Control by Drug Maker

October 3, 2014

NIH To Sponsor Animal Care, Human Protection Workshop

February 21, 1986